Prime Medicine, Inc. (PRME)
PRME Stock Price Chart
Explore Prime Medicine, Inc. interactive price chart. Choose custom timeframes to analyze PRME price movements and trends.
PRME Company Profile
Discover essential business fundamentals and corporate details for Prime Medicine, Inc. (PRME) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Oct 2022
Employees
214.00
Website
https://www.primemedicine.comCEO
Jeremy S. Duffield
Description
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
PRME Financial Timeline
Browse a chronological timeline of Prime Medicine, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.28.
Earnings released on 7 Aug 2025
EPS came in at -$0.41 falling short of the estimated -$0.36 by -13.89%, while revenue for the quarter reached $1.12M , missing expectations by -60.19%.
Earnings released on 8 May 2025
EPS came in at -$0.40 falling short of the estimated -$0.32 by -25.00%, while revenue for the quarter reached $1.45M , missing expectations by -37.69%.
Earnings released on 28 Feb 2025
EPS came in at -$0.31 surpassing the estimated -$0.37 by +16.22%, while revenue for the quarter reached $2.18M , missing expectations by -67.82%.
Earnings released on 12 Nov 2024
EPS came in at -$0.44 falling short of the estimated -$0.43 by -2.33%, while revenue for the quarter reached $209.00K , missing expectations by -97.05%.
Earnings released on 8 Aug 2024
EPS came in at -$0.46 falling short of the estimated -$0.40 by -15.00%, while revenue for the quarter reached $37.77M , beating expectations by +2.22K%.
Earnings released on 10 May 2024
EPS came in at -$0.44 surpassing the estimated -$0.45 by +2.22%, while revenue for the quarter reached $591.00K , missing expectations by -69.25%.
Earnings released on 1 Mar 2024
EPS came in at -$0.56 falling short of the estimated -$0.48 by -16.67%.
Earnings released on 3 Nov 2023
EPS came in at -$0.55 falling short of the estimated -$0.45 by -22.22%.
Earnings released on 7 Aug 2023
EPS came in at -$0.47 falling short of the estimated -$0.42 by -11.90%.
Earnings released on 11 May 2023
EPS came in at -$0.44 falling short of the estimated -$0.42 by -4.76%.
Earnings released on 9 Mar 2023
EPS came in at -$0.56 surpassing the estimated -$0.65 by +13.85%.
Earnings released on 21 Oct 2022
EPS came in at -$0.38 surpassing the estimated -$0.72 by +47.05%.
Earnings released on 30 Jun 2022
EPS came in at -$0.50 .
Earnings released on 31 Mar 2022
EPS came in at -$0.42 .
Earnings released on 31 Dec 2021
EPS came in at -$0.86 .
Earnings released on 30 Sept 2021
EPS came in at -$0.32 .
Earnings released on 30 Jun 2021
EPS came in at $0.05 , while revenue for the quarter reached $9.13M .
Earnings released on 31 Mar 2021
EPS came in at -$11.82 .
Earnings released on 1 Jan 2021
EPS came in at -$0.04 .
PRME Stock Performance
Access detailed PRME performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.